Amneal Pharmaceuticals, Inc.

AMRX

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001723128

C

middle fifth of 367 graded peers in healthcare

rank 179 of 367; percentile 48.6; sampling error 2.5 points; lower is stronger

A B C D E

C, the tortoise




Scoreboard	
Profitability	B percentile 36.0
Solvency	D percentile 75.8
Growth and financing	B percentile 30.4
Reliability	0.94 AUC filers with over $2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025
Peer failure rate	0.52% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	over $2.67B assets total assets $3.7B
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered not computable: distress
Inputs computable	11 of 14
Graded from	filings received through Feb 27, 2026 261 days before the rescan; latest periodic filing 10-Q received Nov 9, 2026
Last close	$21.37 2026-11-13; market equity $7.4B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 27, 2026

Amneal Pharmaceuticals, Inc. (the "Company", "we," "us," or "our") is a diversified, global biopharmaceutical company that develops, manufactures, markets, and distributes a diverse portfolio of essential medicines. Our Affordable Medicines segment includes retail generics, injectables, and biosimilars. In our Specialty segment, we offer a portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders. Through our AvKARE segment, we are a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. We operate principally in the United States ("U.S."), India, and Ireland.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight


Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 36.0						
Gross profitability	30.3%	32.3%		49.7	365	2025-12-31
Return on invested capital	16.5%	9.3%		28.8	74	2025-12-31

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	(7.5%)	(6.6%)		52.3	799	2025-12-31
Gross margin stability, five years	1.0 pts	2.8 pts		13.3	242	2025-12-31
Solvency, sleeve percentile 75.8						
Twelve-month failure probability	not computable	0.08%				
liabilities and a nearby cover-page share count are required at 2026-09-30						
Altman Z double-prime	not computable	(0.31)				
required facts have no common fiscal period end						
Net debt to EBITDA	5.07x	1.82x		82.4	75	2025-12-31
Interest coverage	not computable	(4.51x)				
one or more required annual facts are missing						
Current ratio	2.17x	2.96x		69.2	825	2025-12-31
Growth and financing, sleeve percentile 30.4						
Revenue growth, three-year compound	10.9%	10.1%		48.3	411	2025-12-31
Free cash flow growth, three-year compound	143.5%	11.0%		2.1	95	2025-12-31
Reinvestment rate	161.3%	37.1%		18.4	104	2025-12-31
Asset growth, three years	(1.1%)	2.3%		53.9	693	2025-12-31
Net share issuance, one year	1.5%	2.4%		29.1	627	2026-02-13

Among 367 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
174	Align Technology Inc. (ALGN)	47.3	C	
175	Kymera Therapeutics, Inc. (KYMR)	47.5	C	dilution
176	ClearPoint Neuro, Inc. (CLPT)	47.8	C	
177	ImmunityBio, Inc. (IBRX)	48.1	C	short runway, distress
178	Scynexis Inc. (SCYX)	48.4	C	fortress balance sheet
179	Amneal Pharmaceuticals, Inc. (AMRX)	48.6	C	
180	Macrogenics Inc. (MGNX)	48.9	C	
181	Biodesix Inc. (BDSX)	49.2	C	dilution
182	Savara Inc. (SVRA)	49.5	C	short runway, fortress balance sheet
183	UroGen Pharma Ltd. (URGN)	49.7	C	distress
184	Evolus, Inc. (EOLS)	50.0	C	

What the price implies

at the 2026-11-13 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	86.1%	(1.5%)	87
Distance from 52-week high	(1.5%)	(32.0%)	92
EBIT to enterprise value	3.9%	(1.8%)	72
Free cash flow yield	3.6%	(1.0%)	74
Book value to price	0.07	0.29	20
Sales to price	0.41	0.29	59

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Composite equity issuance, five years	not computable	19.1%	
Relative strength against the sector, log excess return	0.45	(0.18)	87

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score 7 of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$157.4M
Operating cash flow, four quarters	$180.6M
Months of runway	not finite
Days since last periodic filing	6 (10-Q received Nov 9, 2026)
Median daily dollar volume, 63 sessions	$56.9M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$1.1B	2025-12-31	2026-02-27	10-K	26-000011
2	assets	us-gaap:Assets	$3.7B	2025-12-31	2026-02-27	10-K	26-000011
3	operating income	us-gaap:OperatingIncomeLoss	$394.1M	2025-12-31	2026-02-27	10-K	26-000011
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$139.2M	2025-12-31	2026-02-27	10-K	26-000011
5	income tax	us-gaap:IncomeTaxExpenseBenefit	$11.3M	2025-12-31	2026-02-27	10-K	26-000011
6	total debt	us-gaap:LongTermDebt	$2.6B	2025-12-31	2026-02-27	10-K	26-000011
7	book equity	us-gaap:StockholdersEquity	-$70.8M	2025-12-31	2026-02-27	10-K	26-000011
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$282.0M	2025-12-31	2026-02-27	10-K	26-000011
9	total debt	us-gaap:LongTermDebt	$2.4B	2024-12-31	2026-02-27	10-K	26-000011
10	book equity	us-gaap:StockholdersEquity	-$109.3M	2024-12-31	2026-02-27	10-K	26-000011
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$110.6M	2024-12-31	2026-02-27	10-K	26-000011
12	net income	us-gaap:NetIncomeLoss	$72.1M	2025-12-31	2026-02-27	10-K	26-000011
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$340.0M	2025-12-31	2026-02-27	10-K	26-000011
14	assets	us-gaap:Assets	$3.5B	2024-12-31	2026-02-27	10-K	26-000011
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$3.0B	2025-12-31	2026-02-27	10-K	26-000011
16	gross profit	us-gaap:GrossProfit	$1.0B	2024-12-31	2026-02-27	10-K	26-000011
17	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$2.8B	2024-12-31	2026-02-27	10-K	26-000011
18	gross profit	us-gaap:GrossProfit	$820.6M	2023-12-31	2026-02-27	10-K	26-000011
19	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$2.4B	2023-12-31	2026-02-27	10-K	26-000011
20	gross profit	us-gaap:GrossProfit	$784.7M	2022-12-31	2025-02-28	10-K	25-000012
21	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$2.2B	2022-12-31	2025-02-28	10-K	25-000012
22	gross profit	us-gaap:GrossProfit	$769.0M	2021-12-31	2024-03-14	10-K	24-000014
23	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$2.1B	2021-12-31	2024-03-14	10-K	24-000014
24	depreciation amortization	us-gaap:Depreciation	$57.3M	2025-12-31	2026-02-27	10-K	26-000011
25	current assets	us-gaap:AssetsCurrent	$1.9B	2025-12-31	2026-02-27	10-K	26-000011
26	current liabilities	us-gaap:LiabilitiesCurrent	$881.6M	2025-12-31	2026-02-27	10-K	26-000011
27	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$70.1M	2025-12-31	2026-02-27	10-K	26-000011
28	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$295.1M	2024-12-31	2026-02-27	10-K	26-000011
29	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$51.9M	2024-12-31	2026-02-27	10-K	26-000011

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

30	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$345.6M	2023-12-31	2026-02-27	10-K	26-000011
31	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$43.2M	2023-12-31	2026-02-27	10-K	26-000011
32	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$65.1M	2022-12-31	2025-02-28	10-K	25-000012
33	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$46.4M	2022-12-31	2025-02-28	10-K	25-000012
34	current assets	us-gaap:AssetsCurrent	$1.6B	2024-12-31	2026-02-27	10-K	26-000011
35	current liabilities	us-gaap:LiabilitiesCurrent	$1.1B	2024-12-31	2026-02-27	10-K	26-000011
36	assets	us-gaap:Assets	$3.5B	2023-12-31	2025-02-28	10-K	25-000012
37	assets	us-gaap:Assets	$3.8B	2022-12-31	2024-03-14	10-K	24-000014
38	shares outstanding	dei:EntityCommonStockSharesOutstanding	314,629,101	2026-02-13	2026-02-27	10-K	26-000011
39	shares outstanding	dei:EntityCommonStockSharesOutstanding	309,966,341	2025-02-14	2025-02-28	10-K	25-000012

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.